LAVA Therapeutics N.V.
LVTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 77% | -65.1% | 262.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 48.6% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -196.1% | -598.8% | -158.8% | -766.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -209.6% | -618.6% | -164.5% | -791.7% |
| EPS Diluted | -0.94 | -1.57 | -1.23 | -2.14 |
| % Growth | 40.1% | -27.6% | 42.5% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | $0 | -$0 |